



23 May 2012

BIOCOM “LIFE CHANGING” TECHNOLOGY AWARDED TO L-DEX

Brisbane, Australia – **ImpediMed Limited** (ASX: IPD), (“the **Company** or **ImpediMed**”), would like to highlight to all investors it has won an award for the L-Dex U400 last week at the Medical Device & Diagnostics Expo hosted by BIOCOM in California, USA. After local Australian and US media coverage reported on the award, the Company felt it important to share with all shareholders.

The BIOCOM award was for the category of ‘Life Changing’ technology – “for a company that has had the biggest difference on an individual while addressing the greatest medical need”. BIOCOM is the largest regional life science association in the World, representing 560 biotech, pharmaceutical and medical device / diagnostic companies throughout Southern California, USA.

“ImpediMed is excited to receive this award for the U400 limb application for lymphoedema. It helps to build both awareness and recognition in the broader medical community for the need to recognize and address lymphoedema. With the exciting progress in cancer detection and treatment, survivorship issues are now emerging as a key focus in cancer care. For cancer patients, education and ongoing surveillance of lymphoedema can lead to earlier treatment and better outcomes. This has the potential for being life changing for patients when lymphoedema is treated earlier”, said Peggy Brooker, COO & CFO.

A panel of nine judges which included representatives from Johnson & Johnson, Medtronic, Qualcomm Ventures and Sharp HealthCare undertook the Company interviews and judging process.

In addition, the Company would like to bring to the attention of all shareholders two new videos posted to its website. <http://impedimed.com.au/investor-relations/shareholder-services/>. The videos are important, titled “Dr West Video” and “Brisbane Channel 9 News Video”, for shareholders as both clearly describe and demonstrate both the Company product in action, and its clinical value to medical providers and patients.

For further information contact:

Greg Brown
ImpediMed CEO
T: 61-7-3860-3700
Mobile/Cell: +61408281127

About ImpediMed

L-Dex® is a trademark of ImpediMed Limited.

The L-Dex® scale is a tool to aid in the clinical assessment of unilateral lymphoedema of the arm and leg in women and the leg in men by a medical provider.

The L-Dex® scale is not intended to diagnose or predict lymphoedema of an extremity.

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au